Pfizer Recalls Some Lots Of Hypertension Med Due To Potential Cancer-Causing Impurity - Pfizer (NYSE:PFE)

Pfizer Inc PFE voluntarily recalls Accuretic (quinapril HCl/hydrochlorothiazide) and two authorized generic versions due to the presence of nitrosamine, N-nitroso-quinapril, above an acceptable level.
Pfizer will recall six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets, and four lots of quinapril HCl/ hydrochlorothiazide tablets.
Nitrosamines are common in water and foods, including cured and grilled meats, dairy products, and vegetables. Everyone is exposed to some level of nitrosamines. These impurities may increase cancer risk if are exposed to them above acceptable levels over long periods.
Related: Pfizer Pulls Out Additional Lots Of It Anti-Smoking Pill.
These products are indicated for hypertension. To date, Pfizer is not aware of reports of adverse events that have been assessed to be related to this recall.
The product lots were distributed from November 2019 to March 2022.
Wholesalers and distributors with an existing inventory of the listed lots should stop use and distribution and immediately quarantine the product.
Price Action: PFE shares are down 2.30% at $52.95 during the market session on the last check Tuesday.